The company said Anat Ashkenazi resigned as Executive Vice President and Chief Financial Officer on June 5, 2024 to pursue a career opportunity outside the pharmaceutical industry.

1. 01

   The company said Anat Ashkenazi resigned as Executive Vice President and Chief Financial Officer on June 5, 2024 to pursue a career opportunity outside the pharmaceutical industry.

2. 02

   Eli Lilly said Ashkenazi will continue to serve at full capacity in her role and on the Executive Committee through July 2024.

3. 03

   The company said an internal and external search for Ashkenazi's successor is underway.

4. 04

   The company said David A. Ricks, chair and CEO, thanked Ashkenazi for her 23 years of service and her 3 years as CFO. It said she previously served as senior vice president, controller and chief financial officer of Lilly Research Laboratories.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.